enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND’s pivotal cohort planned for 4Q 2026 Pre-Biologics License Application (BLA) meeting with the FDA on track for 4Q 2026 Initiation of BLA submission for detalimogene planned for 4Q 2026 Detalimogene plus surfactant […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
